Compositional and functional changes of low-density lipoprotein during hemodialysis in patients with ESRD11This work is dedicated to Professor Dr. Dietrich Seidel, Klinikum Groβhadern, University of Munich, on the occasion of his 60th birthday.  by Ambrosch, Andreas et al.
Compositional and functional changes of low-density lipoprotein
during hemodialysis in patients with ESRD1
ANDREAS AMBROSCH, UTE DOMROESE, SABINE WESTPHAL, JUTTA DIERKES, WOLFGANG AUGUSTIN,
KLAUS H. NEUMANN, and CLAUS LULEY
Institute of Clinical Chemistry, Department of Pathobiochemistry, and Department of Medicine, Division of Nephrology, University
Hospital of Magdeburg, Magdeburg, Germany
Compositional and functional changes of low-density lipoprotein
during hemodialysis in patients with ESRD.
Background. This study focused on the effects of hemodialysis
on the atherogenic properties of low density lipoprotein (LDL) in
patients with end-stage renal disease (ESRD). The impact of
cholesterol ester transfer protein (CETP) activity and lipolysis on
LDL composition, particularly the changes during hemodialysis,
was investigated.
Methods. Blood was drawn from 15 normotriglyceridemic
(NTG) and 15 hypertriglyceridemic patients [HTG; triglycerides
(TG) ,2.2 mmol/liter] before hemodialysis, during (1.5 hr after
the beginning of anticoagulation) and at the end of treatment. In
each sample, lipid values and CETP activity were measured. LDL
was prepared and characterized by its components and diameters
(2 to 16% PAGGE). To investigate the functional properties of
LDL, fractions obtained from NTG and HTG patients were
incubated with human skin fibroblasts and a cell line of murine
macrophages (P388), and cholesterol ester formation rates were
measured.
Results. In comparison to LDL from NTG patients at baseline,
HTG-LDL were enriched in triglycerides (P , 0.02), depleted in
cholesterol proportion (P , 0.01) and small in size (P , 0.001).
These LDL induced the cholesterol esterification rates (50 mg/mL
LDL-protein) in a twofold greater unsaturation in macrophages
when compared to LDL from NTG patients (P , 0.04). The rates
in fibroblasts were reduced by approximately half (P , 0.05).
During hemodialysis, LDL were decreased in size (P , 0.001) and
depleted in TG (P , 0.01), particularly in the hypertriglyceride-
mic state. Although CETP activity increased during hemodialysis
(P , 0.001), the cholesterol content remained unchanged. When
HTG-LDL obtained during hemodialysis were incubated with
cells, esterification rates particularly in macrophages were mark-
edly accelerated in comparison to the unmodified lipoprotein at
baseline (P , 0.05).
Conclusion. LDL from HTG patients with ESRD was TG-
enriched, CH-depleted and smaller in size. As the intracellular
esterification rates induced by LDL were related to the cellular
uptake, these LDL were a superior substrate for murine macro-
phages with the tendency of intracellular accumulation, and an
inferior substrate for fibroblasts suggesting a decreased uptake by
the specific receptor pathway. TG-depletion of LDL during
hemodialysis, particularly in HTG patients due to a lipase-
mediated TG-hydrolysis, increased these effects in macrophages.
We suggest that the alterations of LDL that occur during repeated
hemodialysis in vivo could contribute to the high prevalence of
premature atherosclerosis found in HTG patients with ESRD.
End-stage renal disease (ESRD) is associated with ac-
celerated atherosclerosis and a high incidence of cardiovas-
cular disease [1, 2]. In the United States, the death rate
from myocardial infarction for patients with ESRD aged
between 45 and 64 years is 24.1 per 1000 patient-years,
which is far in excess of the general population [3, 4].
Although the course of increased atherosclerotic cardiovas-
cular disease in these patients is probably multifactorial,
lipid abnormalities are thought to play a major role [5] and
a number of alterations in lipids have been described.
The primary lipid abnormality found in ESRD is ele-
vated triglyceride (TG) levels that are predominantly due
to reduced lipolysis of triglyceride-rich lipoproteins [6–9],
which is often accompanied by a reduced high-density
lipoprotein (HDL) cholesterol level [10, 11]. These abnor-
malities are present in patients with ESRD who are not on
dialysis as well as patients treated either with hemodialysis
or continuous ambulatory peritoneal dialysis [12, 13]. Ele-
vated TG levels can indicate accumulation of triglyceride-
rich, potentially atherogenic remnant particles, a finding
reported in patients treated with chronic hemodialysis
[14–16].
Low-density lipoprotein (LDL) cholesterol levels are not
elevated in ESRD [17, 18], but changes in size and compo-
sition in association with hypertriglyceridemia could poten-
tially result in increased atherogenicity of LDL particles
[19]. Recently, Luley et al described a small-dense LDL-
pattern for dyslipidemic patients with ESRD and, in addi-
tion, an acute alteration in LDL size during the course of
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hemodialysis [20]. These changes in LDL diameter were
pronounced in dyslipidemic patients and accompanied by
an increase in total LDL-cholesterol during each hemodi-
alysis session. Consequently, it can be theorized that re-
peated hemodialysis in itself has an unfavorable effect on
the atherogenic profile of LDL. In the present study, we
determined the impact of cholesteryl ester transfer protein
(CETP) activity and lipolytic activity on changes in LDL
composition and size, before and during hemodialysis in
normo- and dyslipidemic patients with ESRD. Further-
more, we investigated the functional properties of this
lipoprotein species in vitro in relation to the compositional
changes caused by hemodialysis.
METHODS
Study subjects
A total of 30 patients with ESRD (17 male and 13
female; from the Department of Internal Medicine, Center
for Kidney Disease, University Hospital Magdeburg, Ger-
many) were enrolled in the study. The patients group
consisted of 15 hypertriglyceridemic subjects (total triglyc-
erides . 2.2 mmol/liter) and 15 subjects with normal
plasma triglycerides. All patients were hemodialyzed
against a bicarbonate bath for three to four hours in a
treatment three times weekly. Underlying renal disease
were: diabetic nephropathy (N 5 7), chronic glomerulone-
phritis (N 5 7), small kidneys of unknown cause (N 5 9),
polycystic kidney disease (N 5 3), pyelonephritis (N 5 3),
and Alport syndrome (N 5 1). A total of nine patients were
diabetic: three in the NTG group and six in the HTG group
(7 patients were on hemodialysis because of diabetic ne-
phropathy, 1 because of polycystic kidney disease and 1
because of pyelonephritis). Two patients in the HTG group
and one in the NTG group had a history of renal trans-
plantation with a consecutive transplant dysfunction. In
both groups, the prevalence of a history for coronary artery
disease (CAD), peripheral vascular disease and for stroke
was evaluated: history of CAD in HTG versus NTG
patients 6 of 15 versus 4 of 15; for peripheral vascular
disease 7 of 15 versus 3 of 15; for stroke 4 of 15 versus 0 of
15. Patients with a history of recent myocardial infarction
(within 3 months), unstable angina, severe congestive heart
failure, recent stroke and hypertension with systolic RR .
200 mm Hg (and/or diastolic RR . 105) were excluded. In
addition, no patient had acute bacterial or viral infection
except one patients who had a history of hepatitis C. Since
most of our patients suffered from biochemical hyperpara-
thyroidism (serum parathyroid hormone . 65 ng/liter),
only patients with a symptomatic manifestation (hyperpara-
thyroid bone disease, electrocardiographic signs of hyper-
calcemia) were excluded. Exclusion criteria did not allow to
study patients with cancer (or a history of cancer). In-
formed consent was obtained from all patients.
Study design
Venous blood was drawn after a 12-hour overnight fast
to obtain baseline values. Then, a lipid load test was
performed (a) because patients normally are advised not to
fast before a hemodialysis procedure; (b) to standardize the
postprandial lipoprotein metabolism of the patients [21].
Fifteen minutes after the lipid load, the hemodialysis
procedure began. Furthermore, two additional blood sam-
ples were obtained, one 1.5 hours after the beginning of
hemodialysis (peri-dialytically) and one at the end of each
hemodialysis session (post-dialytically). The anticoagulant
that was employed contained unfractionated heparin dur-
ing each hemodialysis. All patients were within 2% of their
fluid free weight, which was used to calculate the individual
heparin doses. The anticoagulant was administered with a
single intravenous bolus (60 IU/kg body wt) at the begin-
ning of each hemodialysis session and with a subsequent
infusion of 1000 IU/hr.
Lipoproteins
EDTA-plasma (EDTA 1 mg/liter) for lipoprotein analy-
sis was separated without delay by centrifugation at room
temperature and immediately processed or stored at
220°C. For baseline lipoprotein and apoprotein concentra-
tions, very low density lipoprotein (VLDL) and chylomi-
crons were separated from LDL and HDL by a single
centrifugation step over a time period of 18 hours at
100,000 g in a TI 50.4 rotor with a Beckman L-50 ultracen-
trifuge (all from Beckman, Munich, Germany). The layer of
VLDL on the top of the tubes was removed with a
Pasteur-pipette. In the infranatent, the LDL fraction was
precipitated with phosphotungsten acid/MgCl2 reagent be-
fore measurement of HDL composition. The composition
of the VLDL-, HDL-fractions and the infranatent were
determined by measurement of CH, TG, FC and apopro-
teins on an automated Hitachi 911 analyzer (Boehringer,
Mannheim, Germany).
LDL isolation. After separation of chylomicrons by cen-
trifugation at 100,000 g [density (d) , 1.006 g/ml] for 30
minutes, the infranatent was increased to d 5 1.019 mg/liter
by the addition of solid potassium bromide (Sigma, Mu-
nich, Germany) and then centrifuged at 150,000 g (24 hr at
10°C). The floating intermediate density lipoproteins (IDL)
and VLDL were collected. The infranatent was then
brought to d 5 1.060 g/liter and centrifuged at 150,000 g (24
hr at 10°C). The floating LDL was obtained and dialyzed
against a Tris-EDTA buffer for 24 hours at 8°C and
subsequently characterized by their CH, FC, CE, TG and
apo B content.
Lipoprotein component assays
Total apo AI, B, CIII and E were analyzed by immun-
turbidimetric assays using goat antihuman polyclonal anti-
sera (Greiner, Munich, Germany). For measurement of
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cholesterol, we used the CHOD-PAP method (Chol kit®;
Boehringer), for triglycerides and free glycerol the GPO-
PAP method (Triglyceride GPO-PAP kit®; Boehringer)
was used, for free cholesterol the COD-PAP method (free
cholesterol C kit®; WAKO, Munich, Germany) and for
measurement of free fatty acids the ACS-ACOD method
(NEFA C®; WAKO). The CE content was calculated from
total CH and total FC concentrations. The hematocrit was
measured in each sample and used for corrections of
lipoprotein levels.
Nondenaturating polyacrylamide gradient gel
electrophoresis
To estimate LDL particle size, a nondenaturating
polyacrylamide 2 to 16% gradient gel electrophoresis
(PAGGE) was performed, modified from [22]. Briefly, the
stock solutions in the TE-buffer (Tris 210 mM, sodium acid
3 mM, disodium EDTA 3 mM, pH 8.35; all from Sigma)
included in following: the high limit solution acrylamide
152.3 g/liter, bis-acrylamide 7.7 g/liter (16% total, 4%
crosslinker) and glycerol 260 g/liter (all from Sigma), and
the low limit solution acrylamid, 16 g/liter and bis-acryl-
amide 4 g/liter (2% total, 4% crosslinker). The high and the
low limit solutions were made immediately before the
gradient was cast and contained 1 volume high or low limit
solution, 0.0015 vol freshly prepared ammonium persulfate
(100 g/liter; Sigma), and 0.00025 vol 3-dimethylaminopro-
pionitril (TEMED; Sigma). The gradient was generated
with a BioRad Econo-pump (2.6 ml/min; BioRad, Heidel-
berg, Germany), mixed in an external mixing chamber
(BioRad), and cast in a gel slab casting apparatus (180 3
160 mm). The gels were prerun in TE buffer at 60 V for 30
minutes. Samples were made dense with glycerol (1:3
vol/vol), and a volume containing 20 ml plasma samples was
loaded on the gel. Electrophoresis time was two hours at 60
V, 12 hours at 50 V and six hours at 300 V, with a constant
voltage power supply (BioRad) and a constant temperature
of 8°C. At the end of electrophoresis, gels were stained with
Coomassie brilliant blue G (Sigma) for one hour and
destained in a solution of 50% methanol, 10% acetic acid
and 40% water. Latex beads 34 nm (Duke Scientific, Palo
Alto, CA, USA), thyroglobulin 17 nm and ferritin 12.2 nm
(Pharmacia, Freiburg, Germany) were run as standards.
The apparent diameters of LDL were determined by using
a calibration curve generated from standards according to
Williams et al [23]. Reproducibility of the gel analysis of
LDL size was evaluated by analyzing the same LDL
preparation three times. Coefficient of variation of mean
LDL diameters between runs was 5%.
Cholesteryl ester transfer protein activity
Cholesteryl ester transfer protein (CETP) activity was
assessed in a defined system by using a fluorescent cho-
lesteryl linoleate analogue (WAK, Bad Homburg, Germa-
ny). Exogenous donor and acceptor particles (human
VLDL) were combined with the CETP source (EDTA-
plasma) within a total volume of a 10 mM Tris buffer. The
donor particle consisted of a nitrobenzooxadiol-fluorophor
(NBD), which takes advantage of a self-quenching effect on
microemulsion incorporated cholesteryl linoleate. The
CETP-facilitated transfer of fluorescent cholesteryl li-
noleate from the self-quenching donor to the acceptor was
determined by an increase in fluorescence intensity (incu-
bation time 3 hr, 37°C; excitation wavelength 465 nm (EX
456 nm) and emission wavelength of 535 nm (EM 535 nm)
using an LS50 fluorescence spectrometer (Perkin Elmer,
Hannover, Germany). A standard curve to derive the
relation between fluorescence intensity and mass transfer
of cholesteryl linoleate (pmol/3 hr) was generated by
dispersing donor particles in isopropanol in a linear dilu-
tion (cholesteryl linoleate concentration was 80.9 mg/ml).
Spectrally pure (HPLC grade) isopropanol was used as the
solvent to avoid background fluorescence of the blank
(isopropanol). From each sample, triplicates were mea-
sured and the mean fluorescences were calculated. The
intra-assay variance of the mean CETP activities was
calculated with 10.8% and the inter-assay variance with
11.6%. The fluorimetric CETP assay was compared to a
recently described isotopic CETP assay [24], and a good
correlation was found (N 5 25, r 5 0.90, P , 0.001) [25].
Cellular [3H]cholesteryl ester formation in cultured
human fibroblasts and murine macrophages
Cells. Human skin fibroblasts were cultured from biop-
sies of the skin from normal adult donors. The cells were
plated at 7 3 104 cells/35 mm plastic dish in Dulbecco’s
minimal essential medium (DMEM, Sigma), containing
sodium hydrogen carbonate 25 mM, HEPES 20 mM, strep-
tomycin 100 mg/liter, penicillin 105 IU/liter (Sigma) and
fetal calf serum (FCS) 10% (Biochrom, Munich, Germa-
ny). Cultures of fibroblasts in passages 4 to 6 were washed
with Dulbecco’s phosphate-buffered saline (PBS, Sigma)
and incubated in fresh medium containing lipoprotein-
deficient serum 10% (LPDS) to up-regulate apoB/E recep-
tor activity before experiments.
The P388 murine macrophage-like cell line was pur-
chased from American Type Culture Collection (ATCC).
P388 cell were plated at 7 3 104 cells/35 mm dish in RPMI
1640 (Sigma) supplemented with FCS 10%, penicillin,
streptomycin and glutamine. The cells were fed every three
days and were used for experiments within seven days of
plating.
Metabolism of LDL in cell culture. For cellular experi-
ments, pooled LDL (d 5 1.06) from six NTG and six HTG
subjects, respectively, was prepared from fasting plasma
(baseline LDL) and from plasma after heparinization (peri-
dialytically; 1.5 hr after the bolus heparinization at the
beginning of hemodialysis). LDL cholesterol uptake by
cells was estimated by measurement of the stimulation of
[3H]-oleate incorporation into cholesteryl ester [26]. After
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a 48 hour incubation with medium containing LPDS, cells
were washed with PBS and fresh medium containing either
LPDS alone or LPDS with LDL. After 24 hours of incu-
bation with lipoproteins, cultures were washed with PBS
three times and incubated with [3H]-oleate (0.2 mM, 10
mCi/ml; Amersham, Braunschweig, Germany) in the pres-
ence of fatty acid-free albumin (0.07 mM) for two hours at
37°C. The cells were then washed twice with PBS, damaged
in an ultrasound bath and incubated with 1 ml of chloro-
form/methyl alcohol (2:1, vol/vol) to extract lipids. After
two more washes with these solvents, the pooled lipid
extract was dryed and resolubilized in chloroform/methyl
alcohol. The labeled cholesteryl ester was isolated by
thin-layer chromatography on silica gel plates using hexane/
diethyl ether/acetic acid (83:16:1). The protein content of
cell extracts was measured by a modified method of Lowry
et al [27]. All cell experiments were done for three times in
triplicates.
Statistical analysis
The results were presented as medians with minimum
and maximum when data were not normally distributed, or
as mean 6 SD (intracellular esterification rates). Data were
compared using the U-test for interindividual differences
and the Wilcoxon test for intraindividual differences. Dif-
ferences were considered significant at P , 0.05. Coeffi-
cients of skewness and kurtosis were calculated to test
deviations from a normal distribution. Associations be-
tween lipoprotein parameters were determined by calcula-
tion of Pearsons correlation coefficients or by Spearman
rank correlation analysis. For all analysis, the SPSS soft-
ware package (version 6.13) was used.
RESULTS
Baseline characteristics and lipoprotein profile of the
study subjects
General characteristics of the subjects, parameters of
renal function and results of the biochemical lipoprotein
analyses are summarized in Table 1. There were no signif-
icant differences between the HTG and NTG groups
resulting from sex, age, body mass index (BMI) and param-
eters of renal function. The lipoprotein profiles of the HTG
subjects were characterized by elevated total triglycerides
(TG) (P , 0.000), total cholesterol (CH; P , 0.05),
VLDL-TG (P , 0.001) and VLDL-CH concentrations
(P , 0.01). Within the HTG group, no differences were
found between diabetic and non-diabetic patients with
regard to the lipoprotein profile (data not shown). ApoCIII
and apoE corresponded well to the VLDL-TG and varied
significantly between both study groups (P , 0.02 and P ,
0.05, respectively). The plasma free fatty acids (FFA) were
not significantly different between both groups. Whereas
total CH, FC, CE and apo AI in HDL did not differ
between both groups (apolipoprotein data not shown),
HDL-TG was significantly increased in the HTG group
Table 1. Anthropometric data and lipoprotein profile of the study groups
Normolipidemic
group, (NTG), N 5 15
Hyperlipidemic group
(HTG), N 5 15
Significance
P
Age years 49.3 (38–76) 51.6 (41–74) NS
BMI kg/m2 23.7 (17.8–29.9) 19.4 (18.2–21.5) NS
Gender male/female 8/7 9/6
Duration of dialysis months (range) 34 (15–107) 37.5 (25–167) NS
Creatinine mmol/liter 768 (389–1373) 746 (217–1304) NS
Urea mmol/liter 19.3 (14.0–31.8) 20.3 (14.9–28.6) NS
Triglycerides mmol/liter 1.54 (0.43–2.04) 3.67 (2.20–7.41) , 0.000
Cholesterol mmol/liter 5.53 (3.84–8.81) 7.44 (4.32–9.71) , 0.05
ApoCIII mg/dl 13.3 (9.1–28.7) 21.7 (13.4–35.0) , 0.02
ApoE mg/dl 5.13 (2.62–9.17) 6.80 (3.94–9.72) , 0.05
ApoAI mg/dl 1.26 (0.89–2.14) 1.14 (0.85–1.57) NS
VLDL
triglyceride mmol/liter 1.15 (0.06–2.18) 2.44 (1.88–5.98) , 0.001
cholesterol mmol/liter 1.35 (0.18–2.34) 2.13 (1.36–4.86) , 0.01
LDL
cholesterol mmol/liter 3.37 (2.23–6.71) 3.16 (1.96–5.32) NS
triglyceride mmol/liter 0.39 (0.23–0.53) 0.64 (0.30–1.01) , 0.02
cholesteryl ester mmol/liter 2.42 (1.46–5.03) 2.29 (1.22–3.95) NS
unesterified chol. mmol/liter 0.96 (0.60–1.72) 0.81 (0.61–1.34) NS
apoB g/liter 0.85 (0.58–1.70) 1.04 (0.65–1.51) NS
HDL
cholesterol mmol/liter 1.24 (0.86–4.17) 1.04 (0.69–2.11) NS
triglyceride mmol/liter 0.20 (0.13–0.35) 0.25 (0.19–0.38) , 0.03
cholesteryl ester mmol/liter 1.02 (0.69–3.27) 0.87 (0.58–1.81) NS
unesterified cholesterol mmol/liter 0.20 (0.03–0.90) 0.16 (0.08–0.35) NS
FFA mmol/liter 0.36 (0.12–1.31) 0.46 (0.21–0.77) NS
CETP activity pmol/3 hr 22.0 (9.4–37.1) 24.2 (5.3–45.6) NS
Values are median (min-max). FFA is free fatty acids.
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(P , 0.03). In addition, LDL from HTG patients were
enriched in triglycerides in comparison to LDL from NTG
patients (P , 0.05; Table 1) and differed in their triglycer-
ide content per apoB (P , 0.01; Table 2). Furthermore, the
apparent diameter of the major plasma LDL subfraction as
determined by PAGGE was significantly decreased in the
HTG group (P , 0.05; Table 2). According to the classifi-
cation for LDL-phenotypes by Krauss and Burke [28], 11 of
15 of the HTG patients were found to have a phenotype
B-pattern of LDL (,25.5 nm) in contrast to only 4 of 15
NTG participants. The smaller LDL particles were charac-
terized by a decreased CE content (P , 0.04) and FC
content (P , 0.001) per apoB (Table 2) and, as mentionend
above, by an increased TG proportion (P , 0.01, Table 2).
Therefore, LDL diameters correlated inversely with the
TG/apoB ratios (r 5 20.42, P , 0.02; Fig. 1A) and
positively with the FC content per particle (r 5 0.43; P ,
0.03; Fig. 1B). In addition, a significant inverse correlation
was found between the CE and TG proportion per apoB
(r 5 20.45; P , 0.02; Fig. 1C).
Triglyceride depletion of LDL during hemodialysis
One and a half hours (1.5 hr) after the bolus hepariniza-
tion at the beginning of hemodialysis (peri-dialytically), the
LDL-TG/apoB ratios decreased significantly in HTG pa-
tients [LDL-TG/apoB baseline vs. postheparinic: 0.60 (0.25
to 1.23) versus 0.40 (0.22 to 0.97); P , 0.02], but remained
unchanged in the NTG individuals [LDL-TG/apoB base-
line vs. postheparinic: 0.40 (0.24 to 0.91) versus 0.39 (0.23
to 0.78); NS]. The changes in the LDL-TG/apoB ratio
(DLDL-TG/apoB; calculated as the differences between
the baseline LDL-TG/apoB ratios and postheparinic LDL-
TG/apoB ratios) were positively related (r 5 0.38, P , 0.05;
Fig. 2) to the decrease in the LDL diameter (DLDL-
diameter; calculated as differences between baseline LDL
diameter and postheparinic LDL diameter). Up to the end
of the hemodialysis therapy, the LDL-TG/apoB ratios
increased in the HTG patients [LDL-TG/apoB at the end
of therapy, 0.50 (0.18 to 1.08); versus postheparinic values;
P , 0.05], but remained significantly different from base-
line (LDL-TG/apoB ratio on baseline vs. end of therapy,
P , 0.05). The LDL-CE and -FC, and their ratios per apoB
were unaltered in both study groups during the course of
hemodialysis (data not shown).
Baseline CETP activities and CETP activation during
hemodialysis
Baseline CETP activities tended to be increased in the
HTG subjects, but this was not statistically significant
(Table 1). Shortly after the bolus heparinization at the
beginning of the hemodialysis procedure (1.5 hr), CETP
values were increased in the respective study groups in
comparison to baseline (P , 0.001). Nevertheless, the
extent of the peri-dialytical CETP activation was nearly
twice as high in the HTG group when compared with the
NTG subjects (P , 0.001) (Fig. 3). Furthermore, the scope
of the CETP activation (DCETP; calculated as differences
between peri-dialytical CETP activities and baseline CETP
levels) was related (r 5 0.39, P , 0.04) to the extent of the
peri-dialytical FFA increase (DFFA; calculated as differ-
ences between postheparinic FFA concentrations and base-
line FFA levels). Until the end of hemodialysis, CETP
activities decreased in both study groups but remained
elevated when compared with baseline levels (P , 0.01,
respectively; Fig. 3).
Furthermore, a multiple regression analysis was per-
formed to determine a possible effect of CETP activities on
the LDL composition and diameter. No correlation was
found between CETP and LDL-TG (0.26, NS) or LDL-CE
proportion (r 5 20.26, NS), or the LDL diameter (r 5
20.16, NS).
Cellular cholesteryl ester formation in fibroblasts and
murine macrophages P388 induced by LDL
Baseline LDL derived from HTG subjects induced the
esterification rate in fibroblasts in a concentration-depen-
dent, saturable manner but to a minor (60%) degree (with
50 mg lipoprotein) compared to baseline LDL levels from
NTG individuals (P , 0.05; Fig. 4A). On the other hand,
twice as many cholesteryl esters were formed in macro-
phages after preincubation with baseline LDL (50 mg) from
HTG subjects when compared with LDL from NTG indi-
viduals (P , 0.04; Fig. 4B). The esterification rates in
macrophages were unsaturable up to LDL-protein concen-
trations of 100 mg (Fig. 4B).
When fibroblasts and macrophages were preincubated
with LDL preparations derived during hemodialysis from
hypertriglyceridemic patients, intracellular [3H]-cholesteryl







LDL diameter nm 26.83 (23.91–29.37) 23.76 (22.31–26.84) , 0.001
CH/apoB ratio 3.77 (2.12–4.04) 3.16 (1.81–3.89) , 0.01
CE/apoB ratio 2.97 (2.06–3.43) 2.63 (1.79–3.22) , 0.04
FC/apoB ratio 1.08 (0.74–1.59) 0.92 (0.65–1.12) , 0.001
TG/apoB ratio 0.40 (0.24–0.78) 0.60 (0.25–1.23) , 0.01
Values are median (min-max). Abbreviations are: LDL, low density lipoprotein; CH, cholesterol; CE, esterfied cholesterol; FC, unesterified
cholesterol; TG, triglycerides; apo, apolipoprotein.
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Fig. 2. Changes in the triglyceride content per apoB during hemodi-
alysis (expressed as DLDL-TG/apoB) are positively related to the
changes in the LDL diameter (expressed as DLDL-diameter). Symbols
are: (M) hypertriglyceridemic and () normoglyceridemic subjects. r 5
0.38, P , 0.05.
Fig. 3. CETP activities before, during (1.5 hr after the bolus hepariniza-
tion at the beginning of hemodialysis) and after hemodialysis therapy in
normo- (NTG; ) and hypertriglyceridemic (HTG; M) patients. Each time
point represents the median values with minimum and maximum. #P ,
0.001, NTG vs. HTG group; *P , 0.01 and **P , 0.001 vs. baseline levels
within each study group.
Fig. 1. Inverse correlations between the size of the major low-density
lipoprotein (LDL) subfractions (nm) and the triglyceride (TG) content
per particle (A; r 5 0.42, P < 0.02) and the relationship between LDL size
and unesterified cholesterol (FC) per apoB ratios (B; r 5 0.40, P < 0.04)
in normo- and hypertriglyceridemic patients. (C) Inverse correlation
between cholesteryl ester content per particle and the triglyceride content
in LDL within normo- (NTG; ) and hypertriglyceridemic (HTG; M)
study participants (r 5 20.37, P , 0.05).
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ester formation was significantly increased in comparison to
the baseline LDL (P , 0.05, respectively, in Fig. 4 A and
B). Nevertheless, esterification rates in fibroblasts did not
reach the values obtained with LDL from normolipidemic
patients. No differences in the esterification rates were
observed when cells were preincubated with normotriglyc-
eridemic LDL derived during hemodialysis or at baseline
(Fig. 4).
DISCUSSION
This study demonstrates that triglyceride-enriched and
cholesterol-depleted LDL from hypertriglyceridemic pa-
tients with ESRD leads to an increased and unsaturable
cholesterol esterification rate in macrophages and a de-
creased rate in fibroblasts when compared with LDL from
normolipidemic patients. In addition, modification of LDL
lipids during hemodialysis obviously due to a lipase-medi-
ated triglyceride hydrolysis and not to an increased CETP
activity enforces these effects particularly in macrophages.
An atherogenic aspect of hypertriglyceridemia in ESRD
is the prevalence of small and dense LDL fractions known
to be associated with marked changes in the LDL compo-
sition [16, 29–31]. In our hypertriglyceridemic patients,
decreasing LDL diameters were related to decreasing
amounts of unesterified cholesterol and an exchange be-
tween cholesteryl esters and triglycerides, thus proposing a
role of lipid transfer in LDL size reduction. Since acceler-
ated CETP activity might explain the exchange between
triglycerides and cholesteryl esters in LDL, Deckelbaum
and collegues proposed an in vitro model for the size
reduction of isolated LDL involving lipid transfer [32].
Indeed, the baseline CETP activity in our hypertriglyceri-
demic patients tends to be increased but differences did not
reach statistical significance. In addition, CETP did not
correlate with LDL components or particle diameter. This
finding is consistent with results of several other investiga-
tors who have also failed to demonstrate a significant
correlation between CETP activity and LDL particle diam-
eter [33–35]. In this context, it must be taken into consid-
eration that alterations of the cholesterol ester transfer
(CET) are not only determined by CETP levels, but also by
the quantity and the quality of the interacting lipoprotein
particles. There is evidence that both an increase in trig-
lyceride-rich lipoproteins and compositional changes in
VLDL or HDL affected their participation in CET and
potentially drives a higher exchange with LDL at the same
CETP level [36–39]. In this context, it is noteworthy that
our HTG group had increasing triglycerides in HDL and an
increase of cholesterol in VLDL. Both compositional
changes might not only be a result of an accelerated
cholesterol ester transfer, but might also trigger their
process [38, 39]. Furthermore, the increase of cholesterol in
the VLDL-fraction additionally suggests a large amount of
remnant particles in the plasma of our HTG patients.
Although the VLDL-CH levels in our patients are quite
high in comparison to other studies, there is evidence that
HTG patients with ESRD have a severe defect in clearing
cholesterol and triglyceride enriched remnants [9, 14, 40–
42]. In this context, Weintraub and colleagues described a
threefold accumulation of remnants after more than 10
hours postprandially in HTG patients with ESRD in com-
parison to dyslipidemic patients without renal failure [42].
Fig. 4. Cellular [3H]-oleate incorporation into cholesteryl ester in fibroblasts (A) and murine macrophages P388 (B) induced by LDL prepared from
NTG and HTG patients before [HTG-LDL (f) and NTG-LDL () and during hemodialysis [HTG-LDL (hemodialysis) (M) and NTG-LDL
(hemodialysis) ()]. #P , 0.05, between NTG-LDL and the corresponding HTG-LDL concentration; *P , 0.05, between hemodialysis-modified LDL
and baseline LDL within each group and LDL concentration. Values are mean 6 SD.
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One hypothesis concerning an active role of small LDL
particles in the atherogenesis came from observations
about their increased susceptibility to in vitro oxidation.
The increased susceptibility is obviously related to the LDL
composition and might be explained in part by the lower
antioxidant content in small dense LDL [42–44]. Neverthe-
less, only a few studies investigated the oxidizability of LDL
in patients with renal failure, and the results were some-
what contradictory [45–47].
Another hypothesis about the potential atherogenicity of
hypertriglyceridemic LDL might be gained from our cell
culture experiments. In fact, triglyceride-enriched LDL
enhanced the cholesteryl ester formation in cultured fibro-
blasts to a lesser degree than LDL from normolipidemic
subjects. Since apoB-containing lipoproteins are taken up
in fibroblasts by the classical LDL receptor, decreased
intracellular cholesteryl ester formation might be caused by
a decrease in the receptor affinity. Such a circumstance
might be attributed to the higher triglyceride content in
LDL altering the conformation of apoB [36, 48, 49], or to
an oxidative modified recognition site. On the other hand,
the unsaturable esterification rates in murine macrophages–
our in vitro model for the nonspecific receptor pathway–
demonstrated that LDL from HTG subjects enhanced the
uptake more likely than LDL from NTG patients. From all
these facts, it could be proposed that a decreased uptake of
hypertriglyceridemic LDL by the specific pathway in vivo
leads to a prolonged clearance of these particles, followed
by an intracellular deposition of LDL-cholesterol in mac-
rophages [50, 51].
In comparison to baseline levels, the lipid profile in
patients with ESRD was adversely affected during hemo-
dialysis obviously due to the peri-dialytical anticoagulation
[20]. Particularly in hypertriglyceridemic patients, a short-
term decrease in triglyceride rich lipoproteins and a corre-
sponding excess of FFA concentrations illustrated a post-
heparin activation of the lipolytic system. Besides these
effects, an increase in the total LDL cholesterol concentra-
tions and a significant corresponding decrease in the LDL
particle diameter have been observed and recently de-
scribed [20].
The present data suggest that the decrease in LDL
diameters during hemodialysis is caused by a substantial
reduction of the core triglycerides (Fig. 2). These observa-
tions are consistent with findings that lipoprotein lipase
(LPL) as well as the hepatic lipase (HL) induce alterations
in the LDL composition that are characterized by a reduc-
tion in core triglycerides [37, 45, 52], and a conversion
towards subpopulations of smaller size [53, 54]. On the
other hand, Lagrost, Gambert and Lallement [55] demon-
strated in vitro that not lipolysis alone, but sequential
effects of lipolysis and lipid transfer reactions induced
dramatic changes in the mean size of LDL. In our study,
CETP activity increased during hemodialysis with a peak at
1.5 hours after the beginning of anticoagulation and lipid
ingestion. By these facts, it is difficult to determine whether
the increase in CETP activity is the result of postprandial
changes or the effect of hemodialysis procedure. We
prefere the latter interpretation, since several studies in
patients without ESRD usually demonstrated a postpran-
dial CETP peak in correlation to the remnant peak four to
six hours after lipid ingestion [48, 56]. Therefore, our
observations of an early CETP peak more likely illustrated
an effect of hemodialysis than a “physiological” time
course. It might be possible that the increase in CETP
activity during the early phase of hemodialysis is triggered
by the postheparinic excess of FFA. This interpretation is
supported by recent findings that triglyceride-lipolysis in
general enhanced the catalytic efficiency of CETP between
triglyceride-rich and cholesterol-rich lipoproteins [50, 57,
58]. These observations may be result of an increase in
lipid-bound FFA that influenced the binding properties of
CETP to lipoproteins, resulting in an accelerated transfer
rate. In addition, the increased presence of lipids available
for the exchange with cholesterol esters during lipolysis
may promote the formation of shuttle complexes contain-
ing CETP [57]. However, the physiological significance of
the short-term CETP activation during hemodialysis on the
LDL size pattern remains uncertain, since the LDL choles-
terol content was unaltered and the depletion of triglycer-
ides was due to the hydrolytic activity.
From these observations, we propose that compositional
changes of LDL during hemodialysis may also affect the
properties of the lipoprotein surface, thereby modifying the
interaction of the lipoprotein with the receptor pathway.
Indeed, LDL derived from HTG patients during hemodi-
alysis led to an accelerated cholesteryl ester formation in
both fibroblasts and murine macrophages. These findings
are of physiological significance in several respects: since
the LDL-receptor in fibroblasts is regulated by the intra-
cellular cholesterol content, an accelerated uptake of LDL
usually results in a down-regulation of the receptor expres-
sion [51]. An increase in the number of circulating LDL in
vivo may be the respective result and contributes to the
observed increase of LDL-cholesterol [20] during hemodi-
alysis. Since the scavenger receptor activity in macrophages
is not regulated by the cell cholesterol content, increased
uptake can lead to an unsaturable intracellular accumula-
tion of cholesterol and foam cell generation [50, 51].
In conclusion, we believe that small and triglyceride-
enriched LDL particles derived from dyslipidemic patients
with ESRD are an inferior substrate for the specific path-
way in fibroblasts and a superior substrate for the nonspe-
cific pathway in macrophages. In addition, modifications of
the core triglycerides of LDL during hemodialysis may
provide an alternative means of causing macrophages to
take up and accumulate cholesterol. Since these effects
potentially occur in vivo, our data might contribute to the
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understanding of the high prevalence of premature athero-
sclerosis in hypertriglyceridemic patients with ESRD on the
maintenance of hemodialysis.
Reprint requests to Dr. Andreas Ambrosch, Institute of Clinical Chemistry,




Abbreviations used in this article are: apo, apolipoprotein; BMI, body
mass index; CE, esterified cholesterol; CETP, cholesteryl ester transfer
protein; CH, cholesterol; ESRD, end-stage renal disease; FC, unesterified
cholesterol; FFA, free fatty acids; HDL, high density lipoprotein; HL,
hepatic lipase; HTG, hyperlipidemic patients; LDL, low density lipopro-
tein; LPL, lipoprotein lipase; NTG, normolipidemic patients; PAGGE,
nondenaturating polyacrylamide gradient gel electrophoresis; TG, triglyc-
eride; VLDL, very low density lipoprotein.
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